bacillus Calmette-Guerin (BCG)

News alerts, weekly reports and conference planners

Company:

Lacocca Family Foundation

Drug class:

TNF receptor modulator

Related drugs:

‹

IL2-L19-TNF (0)

›

2ms

Phase II Clinical Trial: Multi-dosing the BCG Vaccine for Fibromyalgia (clinicaltrials.gov)

P2, N=0, Withdrawn, Massachusetts General Hospital | Trial completion date: Jan 2023 --> Jan 2027 | Trial primary completion date: Jan 2023 --> Jan 2027

2 months ago

Trial completion date • Trial primary completion date

bacillus Calmette-Guerin (BCG)

7ms

Repeat BCG Vaccinations for the Treatment of Established Type 1 Diabetes (clinicaltrials.gov)

P2, N=150, Active, not recruiting, Massachusetts General Hospital | Trial completion date: Jul 2027 --> Jul 2031 | Trial primary completion date: Jul 2025 --> Jul 2029

7 months ago

Trial completion date • Trial primary completion date

bacillus Calmette-Guerin (BCG)